Background: Pramipexole and ropinirole are relatively new dopamine agonists, both of which have proven efficacy in the treatment of Parkinson’s disease. There is, however, uncertainty regarding differences in the adverse event profiles associated with each drug.
Objective: To compare the adverse events of pramipexole and ropinirole as reported in the peer-reviewed medical literature.
Methods: We systematically reviewed the medical literature to identify randomised controlled trials of pramipexole and ropinirole used in the management of Parkinson’s disease. Computerised databases (including Medline, Embase, the Cochrane Library, and the International Pharmaceutical Abstracts) were used to identify pertinent articles for inclusion in this study. Trials that compared the dopamine agonists to either levodopa or placebo were included.
Analysis: Adverse events with these drugs included dizziness, nausea, hypotension, hallucinations, and somnolence. We made two separate analyses. In the first analysis, we estimated the pooled relative risk (RR) of adverse events with either pramipexole or ropinirole as compared with levodopa. In the second analysis, the pooled RRs of adverse events with pramipexole and ropinirole were compared with placebo. We used the random-effects model of DerSimonian and Laird to estimate the RRs and their corresponding 95% CIs. We tested for study heterogeneity using Q statistics.
Results: There was no significant difference in the risk of dizziness, nausea, or hypotension with either drug individually or in combination when compared with levodopa. The risk of hypotension was approximately four times higher with ropinirole than pramipexole when each drug was individually compared with placebo (6.46 [95% CI 1.47–28.28] for ropinirole, and 1.65 [0.88–3.08] for pramipexole). The pooled RR (for pramipexole and ropinirole combined) of hallucinations was 1.92 (95% CI 1.08–3.43) when compared with levodopa. Relative to placebo, pramipexole had a significantly higher risk of hallucinations than ropinirole (pramipexole 5.2 [95% CI 1.97–13.72] vs ropinirole 2.75 [95% CI 0.55–13.73]). There was no significant difference in the risk of somnolence between the two drugs when each was individually compared with levodopa. When compared with placebo, the pooled RR (pramipexole and ropinirole combined) of somnolence was 3.16 (95% CI 1.62–6.13). Relative to placebo, the risk of somnolence was 2.01 (95% CI 2.17–3.16) with pramipexole and 5.73 (95% CI 2.34–14.01) with ropinirole.
Conclusions: Use of ropinirole seems to be associated with a higher risk of hypotension and somnolence than use of pramipexole when compared with placebo. Use of pramipexole seems to be associated with a higher risk of hallucinations than use of ropinirole when compared with placebo.
This study was funded by the Department of Veterans Affairs and the National Institute of Neurological Disorders and Stroke (NINDS). There are no conflicts of interest to be declared by any of the authors.
Shannon KM, Bennett Jr JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology 1997; 49(3): 724–8PubMedCrossRefGoogle Scholar
Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson’s disease. Neurology 1997; 49(2): 393–9PubMedCrossRefGoogle Scholar
Pinter MM, Pogarel O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999; 66: 436–41PubMedCrossRefGoogle Scholar
Rascol O, Lees AJ, Senard M, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’ disease. Clin Neuropharmacol 1996; 19: 234–45PubMedCrossRefGoogle Scholar
Marek K, Seibyl J, Shoulson I, et al. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653–61CrossRefGoogle Scholar
Whone AL, Remy P, Davis MR, et al. The REAL-PET study: slower progression in early Parkinson’s disease treated with ropinirole compared with L-dopa. Neurology 2002; 58Suppl. 3: A82–3Google Scholar
Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 1999; 150: 206–15PubMedCrossRefGoogle Scholar
Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000; 284; 1931–33Google Scholar
Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson’s disease. Clin Neuropharmacol 1998; 21: 101–7PubMedGoogle Scholar
Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesias in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1489–91CrossRefGoogle Scholar
Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson’s disease. Clin Neuropharmacol 1995; 18: 338–47PubMedCrossRefGoogle Scholar
Sethi KD, O’Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson’s disease: a 12-month experience. Arch Neurol 1998; 55: 1211–6PubMedCrossRefGoogle Scholar
Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA 1997; 278: 125–30Google Scholar
Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72: 713–20PubMedCrossRefGoogle Scholar
Rascol O, Lees AJ, Senard JM, et al. A placebo-controlled study of ropinirole, a new D2 agonist in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. Adv Neurol 1996; 69: 531–4PubMedGoogle Scholar
Schrag AE, Brooks DJ, Brunt E, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson’s disease. Clin Neuropharmacol 1998; 21: 169–75PubMedGoogle Scholar
Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson’s disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998; 13: 39–45PubMedCrossRefGoogle Scholar
Wermuth L. The Danish Pramipexole Group: a double blind placebo-controlled randomized multicenter study of pramipexole in advanced Parkinson’s disease. Eur J Neurol 1998; 5: 235–42PubMedCrossRefGoogle Scholar
Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease: International Pramipexole-Bromocriptine Study Group. Neurology 1997; 49: 1060–5PubMedCrossRefGoogle Scholar
Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease: Ropinirole Study Group. Neurology 1998; 51(4): 1057–62PubMedCrossRefGoogle Scholar
Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52(9): 1908–10PubMedCrossRefGoogle Scholar
Hauser RA, Gauger L, Anderson WM, et al. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000; 15: 658–63PubMedCrossRefGoogle Scholar
Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of seven medical areas. JAMA 2001; 285: 437–43PubMedCrossRefGoogle Scholar